Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 77
- Registration Number
- NCT00755885
- Locations
- 🇬🇧
Velindre Cancer Centre, Whitchurch, Cardiff, United Kingdom
🇬🇧Western General Hospital, Edinburgh, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 1195
- Registration Number
- NCT00638690
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00544440
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00485303
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Beth Israel Hospital, Boston, Massachusetts, United States
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT00474383
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00473512
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT00473746
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 11992
- Registration Number
- NCT00268476
- Locations
- 🇬🇧
West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom
🇬🇧Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧Russells Hall Hospital, Dudley, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.